Schroeder Mark S, EVP, President Diagnostics & COO, has demonstrated a clear selling bias in his recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 42 transactions, all involving Laboratory Corporation of America Holdings (LH), Schroeder has sold shares totaling $8,122,895.54, while purchasing shares worth only $761,085. This disparity highlights a consistent pattern of divestment. Notably, his two most recent transactions, both sales, occurred on March 26, 2026, with values of $393,981.84 and $1,234,548, respectively. These sales follow earlier transactions in February 2026, including sales of $75,081.51, $14,522.53, and $45,485.66, further reinforcing the trend.
Schroeder’s activity in LH shares has been concentrated in a series of transactions over the past year, with significant sales recorded in March and February 2025. On February 28, 2025, he sold shares worth $1,330,638.97, marking one of the largest single transactions in this period. Additionally, a sale of $610,450.45 on March 28, 2025, underscores the sustained divestment strategy. While some filings indicate acquisitions of shares, these are typically accompanied by dispositions or are part of derivative transactions, such as exercises of stock options, which do not represent net purchases. Overall, Schroeder’s trading activity reflects a deliberate reduction in his holdings of LH shares, with no recent purchases to offset the consistent selling pattern.
AI-assisted summary